본문 바로가기

Fermented Oyster Extract Improves Linear Growth in Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial

문서 유형
연구출판물 · 학술지 논문
등재
ESCIKCIScopus
저널 순위
JCR Q3Scopus Q2KCI Q4
저널
PREVENTIVE NUTRITION AND FOOD SCIENCE31(2) · #ART003329000 · 2026
피인용
Scopus 0KCI 0
FWCI (Scopus)
0
JCR IF
JCR 2024 2.5
ISSN
2287-1098

저자

  1. Nagahawatta, D. P.제1저자Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2B7, Canada
  2. Yang, FengqiDepartment of Marine Life Sciences, Jeju National University, Jeju 63243, Korea
  3. Liyanage, N. M.Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2B7, Canada
  4. Kyoung-Min, RheuMarine Bioprocess Co., Ltd., Busan 46048, Korea
  5. Bae-Jin, LeeMarine Bioprocess Co., Ltd., Busan 46048, Korea
  6. 김기봉교신저자Department of Korean Pediatrics, School of Korean Medicine, Pusan National University, Yangsan 50612, Korea
  7. You-Jin, Jeon교신저자Department of Marine Life Sciences, Jeju National University, Jeju 63243, Korea

초록

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of fermentedoyster extract (FGO) as a functional food ingredient for promoting growth in children with idiopathic short stature (ISS). In total, 80 children aged 6-9 years with height below the 25th percentile for age and gender per the Korean NationalGrowth Charts, 2017, were included. They were randomly assigned to receive either 500 mg/d FGO or a matched placebofor 24 weeks. The primary outcome was a change in height while standing; secondary outcomes included growth rate,height standard deviation score (height-SDS), bone age (BA), and levels of growth-related hormones and bone metabolismmarkers. In the intention-to-treat analysis, mean height gain at 24 weeks was 3.22±0.71 and 2.38±0.74 cm in theFGO and placebo groups (P<0.001). Growth rate, height-SDS, BA, serum insulin-like growth factor-1, and urinary deoxypyridinolineincreased significantly in the FGO group compared with the placebo group (P<0.05). In contrast, growthhormone and insulin-like growth factor-binding protein-3 levels did not vary between groups. No serious adverse eventsor clinically meaningful laboratory abnormalities were observed; however, two events of mild rash, possibly related toFGO, led to one drop-out. These findings suggest that standardized FGO may safely augment linear growth and bone metabolismin children with ISS. This product could be developed as a marine-derived functional food for pediatric growthsupport, although more long-term and multicenter studies are warranted to confirm the generalizability of these effectsand FGO durability.

키워드

body heightclinical trialfermentationoystersrandomized controlled trial

식별자

Scopus EID
2-s2.0-105037042041
KCI
ART003329000